MC
RXII

Matisse Capital’s GALENA BIOPHARMA INC COM RXII Stock Holding History

Matisse Capital’s Portfolio RXII Stock Details RXII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-17,000
Closed -$23K – 110
2016
Q1 		$23K Hold
17,000
– – 0.01% 98
2015
Q4 		$25K Buy
+17,000
New +$25K 0.01% 104

Other funds holding RXII

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Matisse Capital's RXII Position: Q2 2016 in Review

Matisse Capital sold out of GALENA BIOPHARMA INC COM (RXII) in Q2 2016, closing a stake of 17,000 shares — an estimated $23K sold.

Matisse Capital first reported a position in RXII in Q4 2015 and held it in 2 quarters. The position peaked at $25K in Q4 2015. 90 funds tracked by Wall St. Rank hold RXII as of Q2 2016.

  • Matisse Capital reported no remaining GALENA BIOPHARMA INC COM position as of Q2 2016 after selling out during the quarter.
  • Matisse Capital sold 17,000 GALENA BIOPHARMA INC COM shares in Q2 2016, an estimated $23K.
  • Matisse Capital first reported a position in GALENA BIOPHARMA INC COM in Q4 2015 and held it in 2 quarters.
  • Matisse Capital's GALENA BIOPHARMA INC COM position peaked at $25K in Q4 2015.
  • 90 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q2 2016.

Based on Matisse Capital's 13F filing for Q2 2016, filed 15 Jul 2016.